The #1-prescribed alpha-1 therapy every year for over 25 years1

  • Effectively raises AAT levels2
    • PROLASTIN-C LIQUID therapy raises AAT levels and antineutrophil elastase activity in the lungs. Although the maintenance of blood serum levels of alpha1-PI above 11 μM has been historically postulated to provide therapeutically relevant antineutrophil elastase protection, this has not been proven
  • A well-established safety profile
  • >4 million infusions worldwide1
  • 15-minute average infusion time at the recommended rate of 0.08 mL/kg/min2
  • Available exclusively through PROLASTIN DIRECT
PROLASTIN-C LIQUID is available ONLY through
the PROLASTIN DIRECT program. To order,
call 1-800-305-7881

PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

Limitations of Use

  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trial
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID.


  1. Data on file, Grifols.
  2. PROLASTIN®-C (alpha1-proteinase inhibitor [human]) Prescribing Information. Grifols.